Earlier this week, Recursion Pharmaceuticals reported that its AI-driven Recursion OS identified 25 drug targets simultaneously and helped cut clinical trial enrollment times by up to half, ...

Recursion Pharmaceuticals (RXRX) is back in focus after management detailed AI driven gains in drug discovery, including 25 new targets identified at once, as investors look ahead to an earnings ...

Recursion Pharmaceuticals (RXRX) closed the most recent trading day at $3.50, moving -6.17% from the previous trading session. The stock's performance was behind the S&P 500's daily loss of 0.41%. At ...

Recursion Pharmaceuticals (NASDAQ:RXRX) has experienced notable share price fluctuations in 2025, falling 27% year-to-date and trading over 55% beneath its 52-week high of $12. In spite of this ...

View Recursion Pharmaceuticals, Inc. Class A RXRX stock quote prices, financial information, real-time forecasts, and company news from CNN.

This week, I had to make one of the most difficult decisions of my career: saying goodbye to 20% of the team at Recursion. The process was extraordinarily painful, and the costs were heartbreakingly ...

Recursion Pharmaceuticals is merging with Exscientia. The new entity will have the backing of quite a few big names in pharma. It'll also have an even more capable drug discovery and development ...

Recursion Pharmaceuticals is harnesing the power of artificial intelligence to rapidly develop new drugs. The drugmaker's former lead candidate failed to show evidence of efficacy in a phase 2 study ...

Recursion claims that its artificial-intelligence-backed drug discovery platform gets smarter each time it pinpoints a new drug candidate—which is why, even with several of those candidates already in ...

Recursion (Nasdaq: RXRX), a leading clinical-stage TechBio company decoding biology to radically improve lives, today announced its participation in the following upcoming investor conferences: ...

Recursion Pharmaceuticals, a drug discovery company that applies artificial intelligence to biology, is shoring up its technology platform by buying two startups that bolster its chemistry ...